HSBC Holdings’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$336M Buy
676,247
+20,804
+3% +$9.22M 0.14% 122
2026
Q1
$293M Buy
655,443
+25,154
+4% +$11.7M 0.15% 119
2025
Q4
$286M Sell
630,289
-7,043
-1% -$3.04M 0.15% 123
2025
Q3
$249M Sell
637,332
-4,629
-0.7% -$1.93M 0.14% 135
2025
Q2
$286M Sell
641,961
-202,714
-24% -$93.4M 0.17% 108
2025
Q1
$409M Sell
844,675
-29,080
-3% -$13.6M 0.25% 66
2024
Q4
$352M Buy
873,755
+18,739
+2% +$8.69M 0.2% 79
2024
Q3
$397M Sell
855,016
-49,726
-5% -$23.9M 0.23% 70
2024
Q2
$425M Buy
904,742
+98,800
+12% +$42.9M 0.26% 68
2024
Q1
$337M Buy
805,942
+191,273
+31% +$80.9M 0.23% 80
2023
Q4
$250M Buy
614,669
+53,862
+10% +$19.9M 0.22% 78
2023
Q3
$195M Sell
560,807
-121,386
-18% -$42.5M 0.2% 83
2023
Q2
$240M Buy
682,193
+118,878
+21% +$40.1M 0.24% 71
2023
Q1
$177M Buy
563,315
+74,725
+15% +$22.4M 0.21% 87
2022
Q4
$141M Buy
488,590
+176,722
+57% +$53.9M 0.16% 122
2022
Q3
$90.9M Sell
311,868
-18,892
-6% -$5.44M 0.15% 118
2022
Q2
$93.2M Sell
330,760
-17,468
-5% -$4.68M 0.13% 134
2022
Q1
$90.5M Sell
348,228
-30,985
-8% -$7.35M 0.11% 159
2021
Q4
$83.6M Sell
379,213
-21,846
-5% -$4.25M 0.08% 241
2021
Q3
$72.9M Buy
401,059
+42,914
+12% +$8.38M 0.07% 234
2021
Q2
$71.6M Buy
358,145
+56,678
+19% +$11.9M 0.08% 243
2021
Q1
$64.7M Sell
301,467
-58,268
-16% -$12.8M 0.08% 260
2020
Q4
$84.1M Buy
359,735
+61,071
+20% +$14M 0.11% 169
2020
Q3
$81.3M Buy
298,664
+74,598
+33% +$20.6M 0.13% 137
2020
Q2
$65M Sell
224,066
-2,983
-1% -$809K 0.12% 140
2020
Q1
$53.5M Buy
227,049
+16,710
+8% +$3.83M 0.12% 153
2019
Q4
$47M Sell
210,339
-64,040
-23% -$13M 0.08% 235
2019
Q3
$46.5M Buy
274,379
+22,616
+9% +$4M 0.09% 241
2019
Q2
$46.2M Buy
251,763
+93,849
+59% +$16.4M 0.09% 226
2019
Q1
$29M Buy
157,914
+12,924
+9% +$2.39M 0.05% 365
2018
Q4
$23.8M Sell
144,990
-66,863
-32% -$11.6M 0.04% 430
2018
Q3
$40.8M Buy
211,853
+17,772
+9% +$3.16M 0.07% 294
2018
Q2
$33M Sell
194,081
-86,920
-31% -$13.5M 0.06% 326
2018
Q1
$45.8M Buy
281,001
+29,050
+12% +$4.74M 0.07% 279
2017
Q4
$37.8M Sell
251,951
-61,476
-20% -$9.1M 0.05% 326
2017
Q3
$47.7M Buy
313,427
+57,668
+23% +$8.68M 0.08% 244
2017
Q2
$33M Buy
255,759
+110,408
+76% +$13.3M 0.06% 331
2017
Q1
$15.9M Buy
145,351
+18,067
+14% +$1.59M 0.03% 542
2016
Q4
$9.38M Buy
127,284
+18,676
+17% +$1.52M 0.02% 748
2016
Q3
$9.47M Buy
108,608
+4,288
+4% +$405K 0.02% 697
2016
Q2
$8.97M Sell
104,320
-20,448
-16% -$1.77M 0.02% 692
2016
Q1
$9.92M Buy
124,768
+8,888
+8% +$804K 0.03% 646
2015
Q4
$14.6M Sell
115,880
-47,648
-29% -$5.75M 0.04% 551
2015
Q3
$17M Sell
163,528
-297,223
-65% -$38.2M 0.04% 443
2015
Q2
$56.9M Buy
460,751
+189,921
+70% +$23.9M 0.12% 191
2015
Q1
$32M Buy
270,830
+22,799
+9% +$2.73M 0.06% 315
2014
Q4
$29.5M Sell
248,031
-50,455
-17% -$5.68M 0.06% 326
2014
Q3
$33.6M Buy
298,486
+100,336
+51% +$9.55M 0.07% 277
2014
Q2
$18.7M Buy
198,150
+15,559
+9% +$1.09M 0.04% 436
2014
Q1
$12.8M Buy
182,591
+32,893
+22% +$2.61M 0.03% 489
2013
Q4
$11.1M Buy
149,698
+29,747
+25% +$2.07M 0.03% 591
2013
Q3
$9.1M Buy
119,951
+114,306
+2,025% +$9.1M 0.02% 640
2013
Q2
$451K Buy
+5,645
New +$416K ﹤0.01% 1226

Other funds holding VRTX

HSBC Holdings's VRTX Position: Q2 2026 in Review

HSBC Holdings increased its Vertex Pharmaceuticals (VRTX) stake by 3.2% in Q2 2026, buying an estimated $9.22M and bringing the position to 676,247 shares worth $336M. The position accounts for 0.14% of the portfolio, ranked #122.

HSBC Holdings first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $425M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • HSBC Holdings held 676,247 shares of Vertex Pharmaceuticals worth $336M as of Q2 2026.
  • HSBC Holdings bought 20,804 Vertex Pharmaceuticals shares in Q2 2026, an estimated $9.22M.
  • Vertex Pharmaceuticals made up 0.14% of HSBC Holdings's portfolio in Q2 2026, its #122 holding.
  • HSBC Holdings first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • HSBC Holdings's Vertex Pharmaceuticals position peaked at $425M in Q2 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.